S,NCTId,eudraCT,study_completion_year,title,acronym,has_results_or_publications_within_1y,has_results_or_publications_within_3y
ðŸŸ¥,NCT00400309,,2007,"A Double Blind, Controlled, Randomised, Clinical Study to Assess the Safety of RepevaxÂ® Administered One Month After RevaxisÂ® or Placebo to Healthy Adults",,False,False
ðŸŸ¥,,2007-002861-11,2007,"An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine administered by Intradermal Route (Flu-ID 15Î¼g) versus an Inactivated adjuvanted Influenza Vaccine administered by Intramuscular Route (AddigripÂ® 15Âµg) in subjects 65 years of age or older",,False,False
ðŸŸ¥,NCT00554333,,2007,"An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine Administered by Intradermal Route (Flu-ID 15Î¼g) Versus an Inactivated Adjuvanted Influenza Vaccine Administered by Intramuscular Route in Subjects 65 Years of Age or Older",,False,False
ðŸŸ¥,NCT00383539,,2007,,,False,False
ðŸŸ¥,,2007-006532-66,2008,"An open-label, single-arm, phase IV study assessing the immunogenicity and safety of ZOSTAVAXïƒ¢ at minimum release specification approaching expiry potency in subjects â‰¥50 years old",,False,False
ðŸŸ¥,NCT00606359,,2008,Immunogenicity of the Inactivated Split-Virion Influenza Vaccine Administered by the Intradermal Route in Renal Transplant Subjects,,False,False
ðŸŸ¥,NCT00447525,2005-001446-16,2008,"Comparison of the Immunogenicity and Safety of a Combined Adsorbed Low Dose Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (REVAXISÂ®) With a Combined Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (DT PolioÂ®) When Given as a Booster Dose at 6 Years of Age",REVAXISÂ® versus DT PolioÂ® as a second booster in 6 year-old children,False,False
ðŸŸ¥,,2008-008724-32,2009,"A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and older",,False,False
ðŸŸ¥,NCT00928785,,2009,"A Randomised, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Tdap-IPV Vaccine and a Tetanus Monovalent Vaccine in Healthy Adults 18 Years of Age and Older",,False,False
ðŸŸ¥,NCT00945438,2009-009977-85,2009,"Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)",Immunogenicity and Safety of a Vaccine Against Influenza (2009-2010 Northern Hemisphere Season),False,False
ðŸŸ¥,NCT00343421,,2009,"Immunogenicity and Safety of PEDIACELÂ®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to InfanrixÂ®-IPV+Hib When Both Vaccines Are Co-Administered With PrevenarÂ® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age",,False,False
ðŸŸ¥,NCT00383526,,2009,,,False,False
ðŸŸ¥,NCT00776438,2007-002104-18,2009,"Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route",,False,False
ðŸŸ¥,NCT01089660,2010-018991-25,2010,"Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects","Open, phase II trial. 200 subjects aged 18 to 60 years will receive the non-adjuvanted vaccine",False,False
ðŸŸ¥,,2010-019835-37,2010,"Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects",,False,False
ðŸŸ¥,NCT01121822,2009-017690-38,2010,"Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)","Immunogenicity and Safety of a Vaccine against Influenza (2010-2011 NH season, intramuscular route)",False,False
ðŸŸ¥,NCT00954798,2009-013344-37,2011,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly Subjects",Immunogenicity and safety of different formulations of intramuscular swine-origin influenza vaccine,False,False
ðŸŸ¥,NCT01249183,,2011,"An Open-label, Randomised, Multicentre Study to Evaluate the Immunogenicity and Safety of a Booster Dose of Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Adsorbed Vaccine (REPEVAX) Administered Concomitantly Versus Non-concomitantly With an Influenza Vaccine (VAXIGRIP) to Subjects of 60 Years of Age and Older",,False,False
ðŸŸ§,NCT00948272,2009-009877-85,2011,Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults,,False,True
ðŸŸ¥,,2010-021068-13,2011,"An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of  a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and older",,False,False
ðŸŸ§,NCT01546909,2011-004458-25,2012,"Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE",Antibody persistence to REVAXIS or DT Polio and Immune response to TETRAVAC-ACELLULAIRE,False,True
ðŸŸ¥,NCT01287949,,2012,"An Open-label, Multicentre Study to Evaluate the Immunogenicity and Safety of One Dose of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older Without a Previous Diphtheria- and Tetanus-containing Booster Within the Last 20 Years",,False,False
ðŸŸ©,NCT04024228,2019-000655-14,2020,Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older,,True,True
ðŸŸ©,NCT03965962,2018-004055-20,2021,"Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With VerorabÂ® and ImovaxÂ® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France",,True,True
ðŸŸ©,NCT04762680,,2023,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent),,True,True
ðŸŸ¥,,2006-000715-19,,A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain).,,False,False
ðŸŸ¥,,2005-002175-32,,Take evaluation and safety of smallpox vaccine (LISTER strain) in naÃ¯ve healthy adults,,False,False
ðŸŸ¥,,2012-005243-25,,"Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route)",,False,False
ðŸŸ¥,NCT00566527,2007-002468-88,,"An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuadÂ® manufactured with rHA administered to healthy children from 9 months of age",,False,False
